Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BBLG vs CNVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CNVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

CNVS Overall Winner 6-Pillar Tally: BBLG 1 – 5 CNVS Matrix Metrics: BBLG 4 – 6 CNVS

As of Nov 20, 2026, Cineverse Corp. (CNVS) is the stronger overall head-to-head candidate over Bone Biologics Corp (BBLG) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BBLG carries a Unified Composite Score of 44.8/100 (HOLD) at $0.27 (N/M Forward P/E, 0.0% operating margin), whereas CNVS carries 35.9/100 (SELL) at $1.73 (38.8x Forward P/E, -12.0% operating margin).

  • Composite vs. Pillar Nuance: While BBLG currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. CNVS 35.9/100 SELL), CNVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-12.0% vs. 0.0% operating margin) and revenue trajectory (+110.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: BBLG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9); meanwhile CNVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BBLG vs CNVS
BBLG NASDAQ
Bone Biologics Corp Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.27
-2.4% 1D
Market Cap $932,329
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.97β · 102% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.7%), weak momentum, RSI 31
RSI-14: 30.9 · SMA20: $0.34 · SMA50: $0.42
CNVS NASDAQ Head-to-Head Winner
Cineverse Corp. Class A Common Stock
Services-Video Tape Rental
$1.73
-5.46% 1D
Market Cap $49.1M
TTM Revenue $99M
Forward P/E 38.8x
Beta / 30D Vol 1.19β · 110% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 15.0 Fund 36.0 Flow 54.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $1.70 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (BBLG 1 – 5 CNVS)

Columns: Metric · BBLG · CNVS
1. Valuation Multiples CNVS
Forward P/E N/M 38.8x
Trailing P/E N/M 38.8x
PEG Ratio N/M 0.46x
EV / Revenue N/M 0.7x
2. Growth & Scale CNVS
Revenue Growth (YoY) +0.0% +110.0%
Earnings Growth (YoY) +0.0% +21.1%
TTM Revenue (USD) N/A $99M
Market Cap $932,329 $49.1M
3. Profitability & Quality BBLG
Gross Margin N/A 42.7%
Operating Margin 0.0% -12.0%
Net Profit Margin 0.0% -2.1%
Return on Equity (ROE) -47.5% -4.6%
4. Balance Sheet & Cash Flow CNVS
Cash Generation (TTM) N/A -$18M
Cash Flow Margin N/A -17.9%
Net Cash / Leverage $1.76 Book/Sh · -47.5% ROE $22M Net Debt (0.65x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CNVS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) 131.8% (28th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CNVS
OpEx & R&D Intensity N/A 54.7% of Rev ($54M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Entertainment Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BBLG (4) vs CNVS (6)
Institutional Metric BBLG CNVS Criterion Row Edge
Market Capitalization
Scale
$932,329 $49.1M Larger Scale CNVS
Trailing P/E Ratio
Valuation
N/M 38.8x Lower Multiple CNVS
Forward P/E Ratio
Valuation
N/M 38.8x Lower Multiple CNVS
Revenue Growth (YoY)
Growth
+0.0% +110.0% Higher Growth CNVS
Operating Margin (TTM)
Profitability
0.0% -12.0% Higher Margin BBLG
Net Profit Margin
Profitability
0.0% -2.1% Higher Margin BBLG
Return on Equity (ROE)
Capital Efficiency
-47.5% -4.6% Higher ROE CNVS
52-Week Range Position
Momentum
0% ($0–$2) 16% ($1–$3) Stronger Trend CNVS
Beta / 30D Volatility
Risk Regime
0.97β · 102% Vol 1.19β · 110% Vol Lower Realized Risk BBLG
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite BBLG
Trailing 12M Revenue (USD)
Operating Scale
N/A $99M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 42.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.46x PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.76 Book/Sh · -47.5% ROE) -$18M ($22M Net Debt (0.65x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CNVS +46.14 pp
BBLG: -33.8% · CNVS: +12.34%
3M Horizon CNVS +23.92 pp
BBLG: -55.81% · CNVS: -31.89%
6M Horizon CNVS +48.6 pp
BBLG: -77.99% · CNVS: -29.39%
1Y Horizon CNVS +50.48 pp
BBLG: -82.9% · CNVS: -32.42%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BBLG Revenue CNVS Revenue BBLG Op. Margin CNVS Op. Margin Margin Leader
FY2019 $1.07B $50M -0.2% -10.5% BBLG
FY2020 $1.07B $0M -0.1% -310.6% BBLG
FY2021 N/A $0M N/A -2245.5% CNVS
FY2022 N/A $60M N/A -1.7% CNVS
FY2023 N/A $70M N/A -13.1% CNVS
FY2024 N/A $50M N/A -32.0% CNVS
FY2025 N/A $80M N/A 10.1% CNVS
FY2026 N/A $70M N/A -23.1% CNVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BBLG BREAKDOWN
104d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BBLG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CNVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 131.8%
IV Percentile 28th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact CNVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BBLG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $932,329 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CNVS Moat Profile Cyclical / Execution-Driven Positioning
Entertainment Operator
Competes within the Entertainment value chain with $49.1M market capitalization and -12.0% operating margin.
OpEx & R&D Reinvestment 54.7% of Rev ($54M)
90D Engineering Disclosures 0 Published

Investor FAQ BBLG vs CNVS Key Questions & Quantitative Answers

As of Nov 20, 2026, Cineverse Corp. (CNVS) is the stronger overall head-to-head candidate over Bone Biologics Corp (BBLG) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BBLG carries a Unified Composite Score of 44.8/100 (HOLD) at $0.27 (N/M Forward P/E, 0.0% operating margin), whereas CNVS carries 35.9/100 (SELL) at $1.73 (38.8x Forward P/E, -12.0% operating margin). Composite vs. Pillar Nuance: While BBLG currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. CNVS 35.9/100 SELL), CNVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-12.0% vs. 0.0% operating margin) and revenue trajectory (+110.0% vs. +0.0% YoY). Technical & Structure Timing Caution: BBLG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9); meanwhile CNVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CNVS leads the Growth & Scale pillar: BBLG posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CNVS at +110.0% YoY revenue growth and +21.1% YoY earnings growth on $99M TTM revenue (42.7% gross margin, -12.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BBLG cumulative revenue shifted +0.0% while CNVS shifted +40.0%. In operating R&D and SG&A reinvestment, BBLG deploys N/A (0 90-day corporate R&D disclosures) versus 54.7% of Rev ($54M) (0 disclosures) for CNVS.

CNVS screens cheaper on headline valuation multiples. BBLG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CNVS trades at 38.8x Forward P/E, 38.8x Trailing P/E, 0.46x PEG, and 0.7x EV/Revenue (-17.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BBLG (-47.5% ROE) versus CNVS (-4.6% ROE) capital efficiency.

In options market volatility and institutional positioning, BBLG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.97β · 102% Vol realized risk). By comparison, CNVS carries 131.8% implied volatility (28th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 110% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.